Authors: Olivia Stevenson, Future Science Group
Researchers from Merck (Darmstadt, Germany) have stated that a resubmission of the New Drug Application for cladribine tablets (CTs) has been accepted for filing by the US FDA. If approved, CTs could be a potential new treatment for patients with relapsing forms of multiple sclerosis (MS).
MS is thought to affect 2.3 million people worldwide, including a large number of young adults. It is currently necessary for most MS treatments to include consistent dosing of medication. However, treatment with CTs would involve only occasional oral treatment. This could lower the burden of treatment, and could perhaps improve the quality of life for MS patients.